Antioxidative stress compositions, methods of preparing and uses thereof
OwnerJohn Michael Pezzutoinventor
Life of this patent
Estimating the term…
Abstract
Antioxidative stress compositions, methods of using antioxidative stress composition and methods of preparing antioxidative stress composition compositions are described. The antioxidative stress compositions may be chemopreventive and/or immunomodulatory. Resveratrol, genistein, ellagic acid, curcumin and quercetin may be included in the antioxidative stress composition compositions individually or in any combination.
Claims16
A dietary supplement comprising at least three active agents selected from the group consisting of resveratrol, genistein, curcumin, quercetin, and salts thereof, wherein the at least three active agents are in an amount that provides a decrease in plasma level of IL-2 after oral or intravenous administration of the dietary supplement to a mammal for three weeks, wherein
- the decrease in plasma level of IL-2 is below 0.4 ng/ml,
- resveratrol comprises from about 1% to about 80% of the dietary supplement by weight, and
- the dietary supplement, after said administration, provides a serum level of resveratrol of from about 3.86 ng/ml to about 154 μg/ml.
A dietary supplement comprising resveratrol or a salt thereof, genistein or a salt thereof, curcumin or a salt thereof, and quercetin or a salt thereof in an amount that provides (i) an increase in expression of CYBB, DUS, GSR, UCP2, and VIMP genes, (ii) a downregulation of ATOX1, CCL5, EPX, MPV17, PRNP and SOD3 gene, after administration of the dietary supplement to a mammal for three weeks, and (iii) a decrease in plasma level of IL-2, wherein
- the decrease in plasma level of IL-2 is below 0.4 ng/ml
- resveratrol comprises from about 1% to about 80% of the dietary supplement by weight, genistein comprises from about 0.5% to about 40% of the dietary supplement by weight, curcumin comprises from about 1% to about 80% of the dietary supplement by weight, and quercetin comprises from about 1% to about 80% of the dietary supplement by weight, and
- the dietary supplement provides (i) a mean serum level of resveratrol of from about 3.86 ng/ml to about 154 μg/ml;
- (ii) a mean serum level of resveratrol-3-O-glucuronide of from about 12.9 ng/ml to about 514 μg/ml;
- (iii) a mean serum level of trans-resveratrol-4′-sulfate of from about 8.9 ng/ml to about 355 μg/ml;
- (iv) a mean serum level of trans-resveratrol-3-sulfate of from about 84.9 ng/ml to about 3397 μg/ml;
- (v) a mean serum level of cis-resveratrol-3-sulfate of from about 2.7 ng/ml to about 108 μg/ml;
- (vi) a mean serum level of resveratrol sulfate total of from about 36.7 ng/ml to about 1467 μg/ml;
- (vii) a mean serum level of genistein-4′-glucuronide of from about 14 μg/ml to about 14167 μg/ml;
- (viii) a mean serum level of genistein-4′-glucuronide of from about 1.7 μg/ml to about 1700 μg/ml;
- (ix) a mean serum level of genistein sulfate of from about 54 μg/ml to about 53836 μg/ml;
- (x) a mean serum level of curcumin glucuronide of from about 6.25 ng/ml to about 250 μg/ml;
- and (xi) a mean serum level of quercetin of from about 0.2 ng/ml to about 8000 μg/ml, based on oral administration of the dietary supplement to a group of eight mammals.
A dietary supplement comprising resveratrol or a salt thereof, genistein or a salt thereof, curcumin or a salt thereof, and quercetin or a salt thereof in an amount that provides (i) a decrease in plasma level of IL-2, (ii) an increase in plasma level of IFN-γ and (iii) a decrease in plasma level of IL-2, after oral or intravenous administration of the dietary supplement to the mammal for three weeks, wherein
- the decrease in plasma level of IL-2 is below 0.4 ng/ml, and
- after said administration, the dietary supplement provides (i) a mean serum level of resveratrol of from about 3.86 ng/ml to about 154 μg/ml;
- (ii) a mean serum level of resveratrol-3-O-glucuronide of from about 12.9 ng/ml to about 514 μg/ml;
- (iii) a mean serum level of trans-resveratrol-4′-sulfate of from about 8.9 ng/ml to about 355 μg/ml;
- (iv) a mean serum level of trans-Resveratrol-3-sulfate of from about 84.9 ng/ml to about 3397 μg/ml;
- (v) a mean serum level of cis-resveratrol-3-sulfate of from about 2.7 ng/ml to about 108 μg/ml;
- (vi) a mean serum level of resveratrol sulfate total of from about 36.7 ng/ml to about 1467 μg/ml;
- (vii) a mean serum level of genistein-4′-glucuronide of from about 14 μg/ml to about 14167 μg/ml;
- (viii) a mean serum level of genistein-4′-glucuronide of from about 1.7 μg/ml to about 1700 μg/ml;
- (ix) a mean serum level of genistein sulfate of from about 54 μg/ml to about 53836 μg/ml;
- (x) a mean serum level of curcumin glucuronide of from about 6.25 ng/ml to about 250 μg/ml;
- and (xi) a mean serum level of quercetin of from about 0.2 ng/ml to about 8000 μg/ml, based on oral administration of the dietary supplement to a group of eight mammals.
Dependencies are inferred from the claim text.